ONC Share Price

Open 0.23 Change Price %
High 0.23 1 Day 0.01 4.55
Low 0.22 1 Week 0.02 9.52
Close 0.23 1 Month -0.01 -4.17
Volume 98864 1 Year -0.15 -39.47
52 Week High 0.75
52 Week Low 0.19
ONC Important Levels
Resistance 2 0.24
Resistance 1 0.24
Pivot 0.23
Support 1 0.22
Support 2 0.22
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
BTO 3.19 -5.62%
BTO 3.19 -5.62%
PLI 2.00 4.71%
PLI 2.00 4.71%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
DA-A 0.22 22.22%
INQ 4.08 21.79%
INQ 4.08 21.79%
CTU-A 0.25 19.05%
MM 0.07 16.67%
MM 0.07 16.67%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
LRT-UN 0.07 -22.22%
TLB 0.60 -16.67%
TLB 0.60 -16.67%
RKN 1.62 -12.43%
RKN 1.62 -12.43%
PWC 0.08 -11.11%
PWC 0.08 -11.11%
ORA 0.16 -11.11%
ORA 0.16 -11.11%
More..

Oncolytics Biotech Inc (TSE: ONC)

ONC Technical Analysis 5
As on 9th Dec 2016 ONC Share Price closed @ 0.23 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.41 & Strong Sell for SHORT-TERM with Stoploss of 0.28 we also expect STOCK to react on Following IMPORTANT LEVELS.
ONC Target for December
1st Target up-side 0.26
2nd Target up-side 0.3
3rd Target up-side 0.34
1st Target down-side 0.16
2nd Target down-side 0.12
3rd Target down-side 0.08
ONC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.oncolyticsbiotech.com
ONC Address
ONC
1167 Kensington Crescent NW
Suite 210
Calgary, AB T2N 1X7
Canada
Phone: 403-670-7377
Fax: 403-283-0858
Interactive Technical Analysis Chart Oncolytics Biotech Inc ( ONC TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Oncolytics Biotech Inc
ONC Business Profile
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.